ABUS Arbutus Biopharma (ABUS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001447028

Quote by TradingView

SEC filings

Insider buyers, 180 days

House members buying, 1 year

STOCK Act, US House only, disclosed up to 45 days after the trade

Funds added, last quarter

13F, latest reported quarter

Conversions, 180 days

Codes C/M, not in net · $2.5M priced

Arbutus Biopharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Arbutus Biopharma Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider

Filed

Value

Since filing

HASTINGS DAVID C

Chief Financial Officer

SELL

2025-02-05 SECtraded 2025-02-04

22,183

$72.8K

+23.2%

Context

1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 2, 2024.
The trade is 13.9% of the 159,724 shares held after it.
3 other insiders sold within 30 days.
96 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: Chief Financial Officer HASTINGS DAVID C sold about $72.8K of ABUS on Feb 4, 2025, the largest insider sale at the company since 2021; 3 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.

Sims Karen

Chief Medical Officer

SELL

2025-02-05 SECtraded 2025-02-04

19,348

$63.5K

+23.2%

Context

1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 2, 2024.
The trade is 18.2% of the 106,194 shares held after it.
3 other insiders sold within 30 days.
96 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: Chief Medical Officer Sims Karen sold about $63.5K of ABUS on Feb 4, 2025, the largest insider sale at the company since 2021; 3 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.

McElhaugh Michael J.

Interim President & CEO

SELL

2025-02-05 SECtraded 2025-02-04

23,790

$78.0K

+23.2%

Context

1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 2, 2024.
The trade is 1.6% of the 1,481,003 shares held after it.
3 other insiders sold within 30 days.
96 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: Interim President & CEO McElhaugh Michael J. sold about $78.0K of ABUS on Feb 4, 2025, the largest insider sale at the company since 2021; 3 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.

Naftzger J. Christopher

General Counsel and CCO

SELL

2025-02-05 SECtraded 2025-02-04

11,333

$37.2K

+23.2%

Context

First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 13.1% of the 86,244 shares held after it.
3 other insiders sold within 30 days.
96 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: General Counsel and CCO Naftzger J. Christopher sold about $37.2K of ABUS on Feb 4, 2025, the largest insider sale at the company since 2021; 3 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.

MANCHESTER KEITH S

Director

SELL

2024-08-16 SECtraded 2024-08-14

8,846

$32.6K

+11.1%

Context

First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 19.2% of the 46,069 shares held after it.
No other insider sold within 30 days.
96 funds added in the 13F quarter to Jun 30, 2026.

Insider activity: Director MANCHESTER KEITH S sold about $32.6K of ABUS on Aug 14, 2024, the largest insider sale at the company since 2021; 96 funds added in the latest 13F quarter.

10 transactions on record

Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.

Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.

See all insider buying · insider selling

Seven facts, ranked against the sector · Rank is not a forecast

Insiders

no insider buys or sells on file

Congress

no House purchase disclosed in the last 12 months

Funds

96 funds bought in last quarter

more than 66% of Pharma & Biotech

Revenue

+128.2% year over year

more than 87% of Pharma & Biotech

Margin

-237.9% net margin

below 68% of Pharma & Biotech

Buybacks

no share repurchases reported

Short interest

22.6% of the float short (float per yahoo 2026-10-26) · 3.5 days to cover · settled 2026-09-30

more than 90% of Pharma & Biotech

What changed in the last 30 days

Nothing new filed in the last 30 days

Watch ABUS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it

Total return over 12 months. Each marker is a filing; hover or tap one for the detail.

-5.2%12M

Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ABUS: institutional holders (13F)

13F holdings, latest reported quarter

Two Seas Capital LP

19,095,583 sh

$91.7M

MORGAN STANLEY

17,698,305 sh

$85.0M

Whitefort Capital Management, LP

15,794,261 sh

$75.8M

BlackRock, Inc.

13,766,071 sh

$66.1M

STATE STREET CORP

7,869,179 sh

$37.8M

Congress trades in ABUS

No Congress trades reported

No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings

Nobody has filed for crossing 5%. That is a fact, not missing data.

ABUS planned insider sales (Form 144)

No planned-sale notices

No insider has filed to sell. Watch this after a run-up.

ABUS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).

Global Endurance Portfolio

$893.4K position · as of 2026-06-30

5.5%

Inception Portfolio

$7.8M position · as of 2026-06-30

2.8%

EQ/Morgan Stanley Small Cap Growth Portfolio

$6.2M position · as of 2026-06-30

1.3%

Morgan Stanley Insight Fund

$13.1M position · as of 2026-06-30

1.1%

Virtus Biotech Clinical Trials Etf

$316.7K position · as of 2026-07-31

0.7%

Janus Henderson Small Cap Growth Alpha ETF

$2.3M position · as of 2026-07-31

0.6%

SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio

Clinical pipeline

4 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.

Phase 1

0 active

Phase 2

0 active

Not applicable

1 active

Matched by sponsor name. Trials run under a subsidiary's own name are not included.

Live price

Daily candles from TradingView, under their licence. No filings marked.

Show the live price chart

Why this name is on the desk

The complete filing record, in one place.

The record shows 96 funds added last quarter. Each figure is a federal filing, dated the day it went public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector by SEC SIC code

UTHR CPIX MRNA REGN LLY ALNY MDGL CITR DNA VRTX NUVL TWST

ABUS financials

Revenue growth

+128.2%

XBRL, annual

Net margin

-237.9%

Fundamentals

Annual figures from XBRL filings. Pick a past date to see them as known then.

	2025-12	2024-12	2023-12	2022-12
Revenue	$14.1M	$6.2M	$18.1M	$39.0M
Operating income	-$38.2M	-$76.3M	-$78.1M	-$65.5M
Net income	-$33.5M	-$69.9M	-$72.8M	-$69.5M
EPS (diluted)	-0.17	-0.38	-0.44	-0.46
Operating cash flow	-$39.6M	-$64.8M	-$85.9M	-$35.4M
Cash	$18.0M	$36.3M	$26.3M	$30.8M
Long-term debt	$0	$0	$0	$0

SEC XBRL, fiscal years, as known on 2026-10-27

ABUS Stock Sonar score 5/7 axes

Find similar shapes Compare

ABUS ranks highest on financial health (99th percentile) and profitability (98th), and lowest on risk and compliance (36th), among Pharma & Biotech peers.

Profitability

Inputs

Return on equity+89.6% · 96 pct, sector of 545
Return on assets+81.1% · 97 pct, sector of 691
Return on invested capitaltax provision or pre-tax income not filed for the four quarters
Return on capital employed+80.8% · 99 pct, sector of 576

Financial health

100

Inputs

Debt to equity0.00x · 100 pct, sector of 352
Cash flow to debtno debt to cover

Growth

Inputs

Revenue growth, YoY+128.2% · 87 pct, sector of 505
Backlog growth, YoYno backlog line filed, or no year-earlier backlog

Institutional and government

Inputs

Funds adding, latest quarter96 · 66 pct, sector of 698
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters

Risk and compliance

Inputs

Short interest, % of float+22.6% · 12 pct, sector of 813
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-K+8.7% · 60 pct, sector of 511

2 not measured: Insider conviction, US patents

Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing

Insider buying Insider selling Congress stock trades Activist 13D stakes Form 144 planned sales CEO pay vs performance All companies

FY Dec 2025	$14.1M
FY Dec 2024	$6.2M
FY Dec 2023	$18.1M
FY Dec 2022	$39.0M
FY Dec 2021	$11.0M

Jun 2026	$1.0M
Mar 2026	$179.1M
Dec 2025	$1.1M
Sep 2025	$529.0K
Jun 2025	$10.7M
Mar 2025	$1.8M
Dec 2024	$1.6M
Sep 2024	$1.3M

FY Dec 2025	-237.9%
FY Dec 2024	-1,133%
FY Dec 2023	-401.6%
FY Dec 2022	-178.0%
FY Dec 2021	-693.9%

Jun 2026	-507.2%
Mar 2026	+94.7%
Dec 2025	-357.4%
Sep 2025	-1,464%
Jun 2025	+23.5%
Mar 2025	-1,390%
Dec 2024	-796.2%
Sep 2024	-1,473%

FY Dec 2025	-$39.6M
FY Dec 2024	-$65.0M
FY Dec 2023	-$86.9M
FY Dec 2022	-$35.9M
FY Dec 2021	-$68.3M

FY Dec 2025	0.00x
FY Dec 2024	0.00x
FY Dec 2023	0.00x
FY Dec 2022	0.00x
FY Dec 2021	0.00x

FY Dec 2025	-38.5%
FY Dec 2024	-68.8%
FY Dec 2023	-60.0%
FY Dec 2022	-45.4%
FY Dec 2021	-56.2%

Jun 2026	+89.6%
Mar 2026	+94.7%
Dec 2025	-38.5%
Sep 2025	-45.9%
Jun 2025	-52.8%
Mar 2025	-79.0%
Dec 2024	-68.8%
Sep 2024	-67.8%

FY Dec 2025	-29.6%
FY Dec 2024	-50.6%
FY Dec 2023	-42.9%
FY Dec 2022	-34.7%
FY Dec 2021	-44.6%

Jun 2026	+81.1%
Mar 2026	+81.5%
Dec 2025	-29.6%
Sep 2025	-35.5%
Jun 2025	-41.2%
Mar 2025	-57.3%
Dec 2024	-50.6%
Sep 2024	-51.3%

FY Dec 2025	-37.3%
FY Dec 2024	-64.1%
FY Dec 2023	-54.9%
FY Dec 2022	-36.8%
FY Dec 2021	-45.8%

Jun 2026	+80.8%
Mar 2026	+84.6%
Dec 2025	-37.3%
Sep 2025	-43.7%
Jun 2025	-50.6%
Mar 2025	-72.6%
Dec 2024	-64.1%
Sep 2024	-64.5%

Jun 2026	6.08x
Mar 2026	5.42x
Dec 2025	n/a
Sep 2025	n/a
Jun 2025	n/a
Mar 2025	n/a
Dec 2024	n/a
Sep 2024	n/a

FY Dec 2025	$907.1M
FY Dec 2024	$583.3M
FY Dec 2023	$393.0M
FY Dec 2022	$333.8M
FY Dec 2021	$416.9M

Jun 2026	$929.0M
Mar 2026	$855.9M
Dec 2025	$907.1M
Sep 2025	$847.9M
Jun 2025	$554.4M
Mar 2025	$631.2M
Dec 2024	$583.3M
Sep 2024	$695.0M

FY Dec 2025	-4.3%
FY Dec 2024	-10.5%
FY Dec 2023	-20.7%
FY Dec 2022	-9.8%
FY Dec 2021	-13.0%

Jun 2026	-2.6%
Mar 2026	-3.9%
Dec 2025	-4.3%
Sep 2025	-5.2%
Jun 2025	-10.2%
Mar 2025	-8.8%
Dec 2024	-10.5%
Sep 2024	-9.9%